Guardant Health (GH) Stock Price, News & Analysis

Company Overview

Guardant Health, Inc. is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes. Guardant360 CDx has received regulatory approval as a companion diagnostic for targeted therapies, while Guardant Reveal offers a blood-based solution for minimal residual disease (MRD) monitoring in early-stage colorectal cancer. Guardant Health is also developing its LUNAR platform for multi-cancer early detection through screening applications.

Guardant Health operates CLIA-certified, CAP-accredited laboratories in the United States and has expanded service offerings across Europe and Asia through partnerships and regional laboratory certifications. The company collaborates with pharmaceutical and biotechnology firms on clinical trials to accelerate drug development and optimize patient selection for targeted therapies. Its commercial and research testing services support oncology practices, academic institutions and life science organizations globally.

The company was co-founded by Helmy Eltoukhy, who serves as Chief Executive Officer, and AmirAli Talasaz, President and Co-founder. Under their leadership, Guardant Health has grown its product pipeline, secured regulatory clearances and forged strategic alliances to advance the use of liquid biopsy in precision oncology.

Key Stats

• Today's Range: $115.30 to $120.35
• 50-Day Range: $78.60 to $119.85
• 52-Week Range: $37.73 to $121.01
• Volume: 1.98 million shs
• Average Volume: 2.17 million shs
• Market Capitalization: $15.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $129.53
• Consensus Rating: Moderate Buy

Guardant Health Stock Analysis - MarketRank™

Guardant Health scored higher than 44% of companies evaluated by MarketBeat, and ranked 652nd out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Guardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for Guardant Health is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Guardant Health are expected to grow in the coming year, from ($2.92) to ($2.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Guardant Health is -35.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guardant Health is -35.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.23% of the float of Guardant Health has been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 6.12.

Change versus previous month

Short interest in Guardant Health has recently increased by 10.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardant Health does not currently pay a dividend.

Dividend Growth

Guardant Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.18

News Sentiment

Guardant Health has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Guardant Health this week, compared to 8 articles on an average week.

Search Interest

26 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.

MarketBeat Follows

9 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,775,166.00 in company stock.

Percentage Held by Insiders

5.60% of the stock of Guardant Health is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/19/2026
• Today: 5/26/2026
• 46th Annual William Blair Growth Stock Conference: 6/02/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• AGM 2026: 6/17/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GH
• CIK: 1576280
• Web: www.guardanthealth.com
• Phone: (855) 698-8887
• Fax: 888-974-4258
• Employees: 2,506
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Guardant Health: $129.53
• High Price Target: $180.00
• Low Price Target: $60.00
• Potential Upside/Downside: +8.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$416.28 million
• Net Margins: -40.10%
• Pretax Margin: -40.21%
• Return on Equity: N/A
• Return on Assets: -26.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.68
• Quick Ratio: 4.39

Sales & Book Value

• Annual Sales: $1.08 billion
• Price / Sales: 14.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.37) per share
• Price / Book: -87.48

Miscellaneous

• Outstanding Shares: 132,600,000
• Free Float: 125,174,000
• Market Cap: $15.89 billion
• Optionable: Not Optionable
• Beta: 1.48